Syn-miR-143 exhibited its growth inhibitory effect by silencing not only the KRAS signaling networks, but also by causing down-regulation of HER2 expression through targeting of DDX6 in HER2-positive GC both in vitro and in vivo. Here, ERBB2 is linked to gastric cancer.